ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.

ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.

Although imatinib mesylate (IM) has transformed the treatment of gastrointestinal stromal tumors (GIST), many patients experience primary/secondary drug resistance. In a previous study, we identified a gene signature, consisting mainly of Kruppel-associated box (KRAB) domain containing zinc finger (...

Full description

Bibliographic Details
Main Authors: Lori Rink, Michael F Ochs, Yan Zhou, Margaret von Mehren, Andrew K Godwin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3556080?pdf=render

Internet

http://europepmc.org/articles/PMC3556080?pdf=render

Similar Items